- Home
- VYX vs DNLI Comparison
VYX vs DNLI Comparison
Compare VYX & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYX
- DNLI
- Stock Information
- Founded
- VYX 1881
- DNLI 2013
- Country
- VYX United States
- DNLI United States
- Employees
- VYX N/A
- DNLI N/A
- Industry
- VYX
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VYX
- DNLI Health Care
- Exchange
- VYX Nasdaq
- DNLI Nasdaq
- Market Cap
- VYX 1.8B
- DNLI 2.1B
- IPO Year
- VYX N/A
- DNLI 2017
- Fundamental
- Price
- VYX $12.50
- DNLI $14.70
- Analyst Decision
- VYX Strong Buy
- DNLI Strong Buy
- Analyst Count
- VYX 6
- DNLI 15
- Target Price
- VYX $14.50
- DNLI $33.85
- AVG Volume (30 Days)
- VYX 1.9M
- DNLI 1.7M
- Earning Date
- VYX 08-07-2025
- DNLI 08-11-2025
- Dividend Yield
- VYX N/A
- DNLI N/A
- EPS Growth
- VYX N/A
- DNLI N/A
- EPS
- VYX 7.32
- DNLI N/A
- Revenue
- VYX $2,677,000,000.00
- DNLI N/A
- Revenue This Year
- VYX N/A
- DNLI N/A
- Revenue Next Year
- VYX N/A
- DNLI $323.34
- P/E Ratio
- VYX $1.66
- DNLI N/A
- Revenue Growth
- VYX N/A
- DNLI N/A
- 52 Week Low
- VYX $7.55
- DNLI $10.57
- 52 Week High
- VYX $15.34
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- VYX 41.13
- DNLI 55.10
- Support Level
- VYX $12.12
- DNLI $12.92
- Resistance Level
- VYX $13.46
- DNLI $15.06
- Average True Range (ATR)
- VYX 0.50
- DNLI 0.78
- MACD
- VYX -0.17
- DNLI 0.08
- Stochastic Oscillator
- VYX 21.66
- DNLI 83.22
About VYX NCR Voyix Corporation
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.